SCHEMBL7708029

SCHEMBL7708029

CC1Oc2ccc(C(Cc3ccc(N(C)C)cc3)NC(=O)OC(C)(C)C)cc2NC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 7/20 0.41
CCKAR P32238 1/20 0.36
CCKBR P32239 1/20 0.36
SMYD3 Q9H7B4 3/20 0.35
IDO1 P14902 1/20 0.35
CTSS P25774 1/20 0.35
CTSK P43235 1/20 0.35
ALDH1A1 P00352 3/20 0.34
LMNA P02545 2/20 0.34
PKM P14618 2/20 0.34
HPGD P15428 2/20 0.34
TSHR P16473 2/20 0.34
HTT P42858 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34
HSD17B10 Q99714 2/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
AGTR1 P30556 1/20 0.34
RAB9A P51151 1/20 0.34
MEN1 O00255 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7092669 0.91 CTSS (0.34) CCKARCCKBRCTSSCTSKALDH1A1
SCHEMBL7713294 0.90 PARP1 (0.42) PARP1CCKARCCKBRSMYD3IDO1
SCHEMBL7708144 0.90 PARP1 (0.42) PARP1CCKARCCKBRSMYD3IDO1
SCHEMBL7713338 0.90 PARP1 (0.42) PARP1CCKARCCKBRSMYD3IDO1
SCHEMBL7713374 0.89 PARP1 (0.50) PARP1CCKARCCKBRIDO1CTSS
SCHEMBL7711371 0.89 PARP1 (0.41) PARP1CCKARCCKBRIDO1ALDH1A1
SCHEMBL7708221 0.87 PARP1 (0.40) PARP1CCKARCCKBRSMYD3IDO1
SCHEMBL7713423 0.86 PARP1 (0.41) PARP1CCKARCCKBRSMYD3IDO1
SCHEMBL7710382 0.85 PARP1 (0.40) PARP1SMYD3HPGDRAB9AMEN1
SCHEMBL7711091 0.84 PARP1 (0.42) PARP1CCKARCCKBRSMYD3IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed